Xiaoshi G. Zhang

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Combination of Postoperative Adjuvant Chemoradiotherapy and Immune Checkpoint Inhibitors Significantly Prolongs Recurrence-Free Survival in Sinonasal Mucosal Melanoma.

Combination of Postoperative Adjuvant Chemoradiotherapy and Immune Checkpoint Inhibitors Significantly Prolongs Recurrence-Free Survival in Sinonasal Mucosal Melanoma.

Journal: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale

Published: March 31, 2026

Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study.

Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study.

Journal: Frontiers in immunology

Published: March 14, 2026

Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study.

Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study.

Journal: Frontiers in oncology

Published: January 06, 2026

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2026

Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies.

Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies.

Journal: MedComm

Published: July 29, 2025

Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma.

Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 17, 2025

Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read Sequencing.

Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read Sequencing.

Journal: MedComm

Published: January 02, 2025

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

Journal: Journal for immunotherapy of cancer

Published: September 08, 2024

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 22, 2023

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.

Journal: The oncologist

Published: August 22, 2023

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors.

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors.

Journal: Nature communications

Published: January 20, 2023

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.

Journal: Frontiers in immunology

Published: October 29, 2022

Showing 1-12 of 48

Last Updated: 09/26/2026